Table 2.
Response and outcome assessment between treatment with regorafenib or an immune checkpoint inhibitor
| Review according to mRECIST | Regorafenib (n = 58) | ICI (n = 31) | p-value |
|---|---|---|---|
| AFP decrease 20% from baselinea, median (IQR) | 14 (31.8) | 10 (35.7) | 0.93 |
| Treatment response, n (%) | |||
| Complete response | 0 (0.0) | 2 (6.5) | 0.34 |
| Partial response | 4 (6.9) | 3 (9.7) | |
| Stable disease | 38 (65.5) | 16 (51.6) | |
| Progressive disease | 12 (20.7) | 7 (22.6) | |
| Not evaluable | 4 (6.9) | 3 (9.7) | |
| Objective response rate, n (%) | 4 (6.9) | 5 (16.1) | 0.31 |
| Disease control rate, n (%) | 42 (72.4) | 21 (67.7) | 0.83 |
| Follow up duration (months), median (IQR) | 6.92 (3.73, 11.48) | 8.03 (3.61, 21.95) | 0.39 |
| Overall survival (months), median (95% CI) | 8 (9.2, NA) | 13.3 (8.3, NA) | 0.37 |
| Progression-free survival (months), median (95% CI) | 2.6 (2.4, 9.0) | 3.0 (2.5, 4.7) | 0.72 |
mRECIST, modified Response Evaluation Criteria in Solid Tumors; ICI, immune checkpoint inhibitor; AFP, alpha fetoprotein.
a
Patients with a baseline AFP level < 10 were excluded from AFP decrease by 20% analysis.